Effects of insulin combined with idebenone on blood-brain barrier permeability in diabetic rats

Journal of Neuroscience Research

Volumn 93, Issue 4, 2015, Pages 666-677

  Sun, Yan Na ^a   Liu, Li Bo ^a   Xue, Yi Xue ^a   Wang, Ping ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Blood brain barrier; Diabetes; Idebenone; Insulin; Tight junction

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CLAUDIN 5; GLUCOSE; IDEBENONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; OCCLUDIN; PROTEIN ZO1; REACTIVE OXYGEN METABOLITE; ANTIDIABETIC AGENT; ANTIOXIDANT; NUCLEOPROTEIN; UBIQUINONE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BODY WEIGHT; BRAIN BLOOD VESSEL; CONTROLLED STUDY; DRUG EFFECT; DRUG PENETRATION; DRUG POTENTIATION; FLUID INTAKE; GLUCOSE BLOOD LEVEL; MALE; MICROVASCULATURE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TIGHT JUNCTION; TRANSMISSION ELECTRON MICROSCOPY; TREATMENT DURATION; UPREGULATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; CAPILLARY PERMEABILITY; CHEMICALLY INDUCED; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODEL; DRUG EFFECTS; METABOLISM; NONPARAMETRIC TEST; PATHOLOGY; PATHOPHYSIOLOGY; ULTRASTRUCTURE; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; NUCLEOPROTEINS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; STATISTICS, NONPARAMETRIC; UBIQUINONE;

EID: 84922907372     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23511     Document Type: Article

References (65)

1. Acharya NK, Levin EC, Clifford PM, Han M, Tourtellotte R, Chamberlain D, Pollaro M, Coretti NJ, Kosciuk MC, Nagele EP, Demarshall C, Freeman T, Shi Y, Guan C, Macphee CH, Wilensky RL, Nagele RG. 2013. Diabetes and hypercholesterolemia increase blood-brain barrier permeability and brain amyloid deposition: beneficial effects of the LpPLA2 inhibitor darapladib. J Alzheimers Dis 35:179-198.
2. Aslam M, Ahmad N, Srivastava R, Hemmer B. 2012. TNF-alpha induced NF-κB signaling and p65 (RelA) overexpression repress Cldn5 promoter in mouse brain endothelial cells. Cytokine 57:269-275.
3. Biessels GJ, Bravenboer B, Gispen WH. 2004. Glucose, insulin, and the brain: modulation of cognition and synaptic plasticity in health and disease: a preface. Eur J Pharmacol 490:1-4.
4. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. 2006. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5:64-74.
5. Brownlee M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820.
6. Bucala R, Cerami A. 1992. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 23:1-34.
7. Carbone C, Pignatello R, Musumeci T, Puglisi G. 2012. Chemical and technological delivery systems for idebenone: a review of literature production. Expert Opin Drug Deliv 9:1377-1392.
8. Chaturvedi RK, Beal MF. 2008. Mitochondrial approaches for neuroprotection. Ann N Y Acad Sci 1147:395-412.
9. Chehade JM, Haas MJ, Mooradian AD. 2002. Diabetes-related changes in rat cerebral occludin and zonula occludens-1 (ZO-1) expression. Neurochem Res 27:249-252.
10. Cheng C, Tsuneyama K, Kominami R, Shinohara H, Sakurai S, Yonekura H, Watanabe T, Takano Y, Yamamoto H, Yamamoto Y. 2005. Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol 18:1385-1396.
11. Dai J, Vrensen GF, Schlingemann RO. 2002. Blood-brain barrier integrity is unaltered in human brain cortex with diabetes mellitus. Brain Res 954:311-316.
12. Dong KK, Damaghi N, Kibitel J, Canning MT, Smiles KA, Yarosh DB. 2007. A comparison of the relative antioxidant potency of L-ergothioneine and idebenone. J Cosmet Dermatol 6:183-188.
13. Ennis SR, Betz AL. 1986. Sucrose permeability of the blood-retinal and blood-brain barriers. Effects of diabetes, hypertonicity, and iodate. Invest Ophthalmol Vis Sci 27:1095-1102.
14. Feldman EL, Stevens MJ, Greene DA. 1997. Pathogenesis of diabetic neuropathy. Clin Neurosci 4:365-370.
15. Gandhi S, Srinivasan BP, Akarte AS. 2013. Potential nephrotoxic effects produced by steroidal saponins from hydro-alcoholic extract of Tribulus terrestris in STZ-induced diabetic rats. Toxicol Mech Methods 23:548-557.
16. Gispen WH, Biessels GJ. 2000. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 23:542-549.
17. Gutzmann H, Hadler D. 1998. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. J Neural Transm Suppl 54:301-310.
18. Han Wei, Dan Wei, Shuo Yi, Fang Zhang, Wenjun Ding. 2011. Oxidative stress induced by urban fine particles in cultured EA.hy926 cells. Hum Exp Toxicol 30:579-590.
19. Hawkins BT, Davis TP. 2005. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 57:173-185.
20. Hawkins BT, Lundeen TF, Norwood KM, Brooks HL, Egleton RD. 2007. Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia 50:202-211.
21. Hovsepyan MR, Haas MJ, Boyajyan AS, Guevorkyan AA, Mamikonyan AA, Myers SE, Mooradian AD. 2004. Astrocytic and neuronal biochemical markers in the sera of subjects with diabetes mellitus. Neurosci Lett 369:224-227.
22. Iwata A, Koike F, Arasaki K, Tamaki M. 1999. Blood-brain barrier destruction in hyperglycemic chorea in a patient with poorly controlled diabetes. J Neurol Sci 163:90-93.
23. Jiang H, Yu P, Qian DH, Qin ZX, Sun XJ, Yu J, Huang L. 2013. Hydrogen-rich medium suppresses the generation of reactive oxygen species, elevates the Bcl-2/Bax ratio, and inhibits advanced glycation end product-induced apoptosis. Int J Mol Med 31:1381-1387.
24. Jiang LY, Tang SS, Wang XY, Liu LP, Long Y, Hu M, Liao MX, Ding QL, Hu W, Li JC, Hong H. 2012. PPARγ agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus. CNS Neurosci Ther 18:659-666.
25. Jiao HX, Wang ZH, Liu YH, Wang P, Xue YX. 2011. Specific role of tight junction proteins claudin-5, occludin, and ZO-1 of the blood-brain barrier in a focal cerebral ischemic insult. J Mol Neurosci 44:130-139.
26. Kapitulnik J, Benaim C, Sasson S. 2012. Endothelial cells derived from the blood-brain barrier and islets of Langerhans differ in their response to the effects of bilirubin on oxidative stress under hyperglycemic conditions. Front Pharmacol 3:131.
27. Kowluru RA, Kanwar M. 2007. Effects of curcumin on retinal oxidative stress and inflammation in diabetes. Nutr Metab 4:8.
28. Kuribayashi M, Wang J, Fujiwara O, Doi Y, Nabae K, Tamano S, Ogiso T, Asamoto M, Shirai T. 2005. Lack of effects of 1439 MHz electromagnetic near field exposure on the blood-brain barrier in immature and young rats. Bioelectromagnetics 26:578-588.
29. Le Bras M, Clément MV, Pervaiz S, Brenner C. 2005. Reactive oxygen species and the mitochondrial signaling pathway of cell death. Histol Histopathol 20:205-219.
30. Lee BH, Lee CC, Cheng YH, Chang WC, Hsu WH, Wu SC. 2013. Graptopetalum paraguayense and resveratrol ameliorate carboxymethyllysine (CML)-induced pancreas dysfunction and hyperglycemia. Food Chem Toxicol 62:492-498.
31. Like AA, Rossini AA. 1976. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 193:415-417.
32. Liu J, Wang S, Feng L, Ma D, Fu Q, Song Y, Jia X, Ma S. 2013. Hypoglycemic and antioxidant activities of paeonol and its beneficial effect on diabetic encephalopathy in streptozotocin-induced diabetic rats. J Med Food 16:577-586.
33. Liu LP, Hong H, Liao JM, Wang TS, Wu J, Chen SS, Li YQ, Long Y, Xia YZ. 2009. Upregulation of RAGE at the blood-brain barrier in streptozotocin-induced diabetic mice. Synapse 63:636-642.
34. Lu M, Xu L, Li B, Zhang W, Zhang C, Feng H, Cui X, Gao H. 2010. Protective effects of grape seed proanthocyanidin extracts on cerebral cortex of streptozotocin-induced diabetic rats through modulating AGEs/RAGE/NF-kappaB pathway. J Nutr Sci Vitaminol 56:87-97.
35. Mancuso M, Orsucci D, Choub A, Siciliano G. 2010. Current and emerging treatment options in the management of Friedreich ataxia. Neuropsychiatr Dis Treat 6:491-499.
36. Manschot SM, Biessels GJ, Cameron NE, Cotter MA, Kamal A, Kappelle LJ, Gispen WH. 2003. Angiotensin converting enzyme inhibition partially prevents deficits in water maze performance, hippocampal synaptic plasticity, and cerebral blood flow in streptozotocin-diabetic rats. Brain Res 966:274-282.
37. Mitic LL, Anderson JM. 1998. Molecular architecture of tight junctions. Annu Rev Physiol 60:121-142.
38. Mohammad G, Siddiquei MM, Othman A, Al-Shabrawey M, Abu El-Asrar AM. 2013. High-mobility group box-1 protein activates inflammatory signaling pathway components and disrupts retinal vascular-barrier in the diabetic retina. Exp Eye Res 107:101-109.
39. Molino Y, Jabès F, Lacassagne E, Gaudin N, Khrestchatisky M. 2014. Setting up an in vitro model of rat blood-brain barrier (BBB): a focus on BBB impermeability and receptor-mediated transport. J Vis Exp 88:e51278.
40. Mooradian AD, Haas MJ, Batejko O, Hovsepyan M, Feman SS. 2005. Statins ameliorate endothelial barrier permeability changes in the cerebral tissue of streptozotocin-induced diabetic rats. Diabetes 54:2977-2982.
41. Nedić O, Rattan SI, Grune T, Trougakos IP. 2013. Molecular effects of advanced glycation end products on cell signalling pathways, ageing, and pathophysiology. Free Radic Res 47(Suppl 1):28-38.
42. Negre-Salvayre A, Salvayre R, Augé N, Pamplona R, Portero-Otín M. 2009. Hyperglycemia and glycation in diabetic complications. Antioxid Redox Signal 11:3071-3109.
43. Ojima A, Matsui T, Maeda S, Takeuchi M, Yamagishi S. 2012. Glucose-dependent insulinotropic polypeptide (GIP) inhibits signaling pathways of advanced glycation end products (AGEs) in endothelial cells via its antioxidative properties. Horm Metab Res 44:501-505.
44. Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM. 2005. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15:16R-28R.
45. 2 generation in brown fat mitochondria by idebenone. Biochem Biophys Res Commun 339:362-366.
46. Rechthand E, Smith QR, Latker CH, Rapoport SI. 1987. Altered blood-nerve barrier permeability to small molecules in experimental diabetes mellitus. J Neuropathol Exp Neurol 46:302-314.
47. Reno CM, Tanoli T, Bree A, Daphna-Iken D, Cui C, Maloney SE, Wozniak DF, Fisher SJ. 2013. Antecedent glycemic control reduces severe hypoglycemia-induced neuronal damage in diabetic rats. Am J Physiol Endocrinol Metab 304:E1331-E1337.
48. Ristow M. 2004. Neurodegenerative disorders associated with diabetes mellitus. J Mol Med 82:510-529.
49. Roldi LP, Pereira RV, Tronchini EA, Rizo GV, Scoaris CR, Zanoni JN, Natali MR. 2009. Vitamin E (α-tocopherol) supplementation in diabetic rats: effects on the proximal colon. BMC Gastroenterol 9:88.
50. Schulingkamp RJ, Pagano TC, Hung D, Raffa RB. 2000. Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci Biobehav Rev 24:855-872.
51. Sena CM, Matafome P, Crisóstomo J, Rodrigues L, Fernandes R, Pereira P, Seiça RM. 2012. Methylglyoxal promotes oxidative stress and endothelial dysfunction. Pharmacol Res 65:497-506.
52. Sena CM, Pereira AM, Seiça R. 2013. Endothelial dysfunction: a major mediator of diabeticvascular disease. Biochim Biophys Acta 1832:2216-2231.
53. Sheth P, Basuroy S, Li C, Naren AP, Rao RK. 2003. Role of phosphatidylinositol 3-kinase in oxidative stress-induced disruption of tight junctions. J Biol Chem 278:49239-49245.
54. Shimizu F, Sano Y, Tominaga O, Maeda T, Abe MA, Kanda T. 2013. Advanced glycation end-products disrupt the blood-brain barrier by stimulating the release of transforming growth factor-β by pericytes and vascular endothelial growth factor and matrix metalloproteinase-2 by endothelial cells in vitro. Neurobiol Aging 34:1902-1912.
55. Singh VP, Bali A, Singh N, Jaggi AS. 2014. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol 18:1-14.
56. Sohn E, Kim J, Jeong IH, Kim CS, Kim YS, Kim JS. 2011. Combination of medicinal herbs KIOM-79 reduces advanced glycation end product accumulation and the expression of inflammatory factors in the aorta of Zucker diabetic fatty rats. Evid Based Complement Alternat Med 2011:784136.
57. Starr JM, Wardlaw J, Ferguson K, MacLullich A, Deary IJ, Marshall I. 2003. Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonanceimaging. J Neurol Neurosurg Psychiatry 74:70-76.
58. Stewart PA, Hayakawa K, Farrell CL, Del Maestro RF. 1987. Quantitative study of microvessel ultrastructure in human peritumoral brain tissue. Evidence for a blood-brain barrier defect. J Neurosurg 67:697-705.
59. Stirban A, Gawlowski T, Roden M. 2013. Vascular effects of advanced glycation endproducts: clinical effects and molecular mechanisms. Mol Metab 3:94-108.
60. Urich E, Lazic SE, Molnos J, Wells I, Freskgård PO. 2012. Transcriptional profiling of human brain endothelial cells reveals key properties crucial for predictive in vitro blood-brain barrier models. PLoS One 7:e38149.
61. Weyer G, Babej-Dölle RM, Hadler D, Hofmann S, Herrmann WM. 1997. A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. Neuropsychobiology 36:73-82.
62. Xie H, Xue YX, Liu LB, Liu YH, Wang P. 2012. Role of RhoA/ROCK signaling in endothelial-monocyte-activating polypeptide II opening of the blood-tumor barrier: role of RhoA/ROCK signaling in EMAP II opening of the BTB. J Mol Neurosci 46:666-676.
63. Yamada K, Tanaka T, Han D, Senzaki K, Kameyama T, Nabeshima T. 1999. Protective effects of idebenone and alpha-tocopherol on beta-amyloid-(1-42)-induced learning and memory deficits in rats: implication of oxidative stress in beta-amyloid-induced neurotoxicity in vivo. Eur J Neurosci 11:83-90.
64. Yang S, Chen Y, Deng X, Jiang W, Li B, Fu Z, Du M, Ding R. 2013. Hemoglobin-induced nitric oxide synthase overexpression and nitric oxide production contribute to blood-brain barrier disruption in the rat. J Mol Neurosci 51:352-363.
65. Yau PL, Javier DC, Ryan CM, Tsui WH, Ardekani BA, Ten S, Convit A. 2010. Preliminary evidence for brain complications in obese adolescents with type 2 diabetes mellitus. Diabetologia 53:2298-2306.